PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32377702-0	2020	Juglone potentiates BRAF inhibitor-induced apoptosis in melanoma through reactive oxygen species and the p38-p53 pathway.	juglone	0-7	tumor protein p53	Homo sapiens	109-112	
16271620-6	2005	Surprisingly, juglone caused a drastic reduction of the basal level of p53 in human fibroblasts and this loss could not be fully rescued by proteasome and calpain I inhibitors.	juglone	14-21	tumor protein p53	Homo sapiens	71-74	
32377702-9	2020	In conclusion, juglone potentiated BRAF inhibitor-induced apoptosis in resistant melanoma cells, and these effects occurred partially through ROS and the p38-p53 pathway, suggesting the potential of juglone as a sensitizer to BRAF inhibitors in the treatment of melanoma.	juglone	199-206	tumor protein p53	Homo sapiens	158-161	
32377702-7	2020	Moreover, juglone combined with PLX4032 markedly increased the intracellular level of reactive oxygen species (ROS) and activated p38 and p53, as compared with juglone alone or PLX4032 alone.	juglone	10-17	tumor protein p53	Homo sapiens	138-141	
31283929-0	2019	ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro.	juglone	32-39	tumor protein p53	Homo sapiens	14-17	
29039537-10	2017	In conclusion, juglone potentiated TRAIL-induced apoptosis in melanoma cells, and these effects were partially mediated through the ROS-p38-p53 pathway.	juglone	15-22	tumor protein p53	Homo sapiens	140-143	
29039537-0	2017	Juglone potentiates TRAIL-induced apoptosis in human melanoma cells via activating the ROS-p38-p53 pathway.	juglone	0-7	tumor protein p53	Homo sapiens	95-98	
29039537-8	2017	However, exposure to TRAIL in combination with juglone markedly increased the production of ROS, activated p38 and increased p53, compared with the cells treated with either juglone or TRAIL alone.	juglone	47-54	tumor protein p53	Homo sapiens	125-128